Cell type-specific proteasomal processing of HIV-1 Gag-p24 results in an altered epitope repertoire

Journal of Virology

Volumn 85, Issue 4, 2011, Pages 1541-1553

  Steers, Nicholas J ^a,b   Currier, Jeffrey R ^a,b   Kijak, Gustavo H ^a,b   Di Targiani, Robert C ^b   Saxena, Ashima ^b   Marovich, Mary A ^b   Kim, Jerome H ^b   Michael, Nelson L ^b   Alving, Carl R ^b   Rao, Mangala ^b  

^a HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

^b WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GAG PROTEIN; GAMMA INTERFERON; HLA B27 ANTIGEN; HLA B35 ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PEPTIDE FRAGMENT; PROTEASOME; PROTEIN PRECURSOR;

ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL TYPE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DISEASE COURSE; ENZYME DEGRADATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; MASS SPECTROMETRY; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN CLEAVAGE; T LYMPHOCYTE ACTIVATION;

AMINO ACID SEQUENCE; CD4-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; EPITOPES, T-LYMPHOCYTE; HIV CORE PROTEIN P24; HIV-1; HLA-B27 ANTIGEN; HLA-B35 ANTIGEN; HUMANS; LYMPHOCYTE ACTIVATION; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; PROTEASOME ENDOPEPTIDASE COMPLEX;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 78951492056     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01790-10     Document Type: Article

References (71)

1. Ackerman, A. L., A. Giodini, and P. Cresswell. 2006. A role for the endoplasmic reticulum protein retrotranslocation machinery during crosspresentation by dendritic cells. Immunity 25:607-617.
2. Altfeld, M., et al. 2003. Influence of HLA-B57 on clinical presentation and viral control during acute HIV-1 infection. AIDS 17:2581-2591.
3. Bansal, A., et al. 2007. Immunological control of chronic HIV-1 infection: HLA-mediated immune function and viral evolution in adolescents. AIDS 21:2387-2397.
4. Barouch, D. H., et al. 2010. Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys. Nat. Med. 16:319-323.
5. Basler, M., N. Youhnovski, M. Van Den Broek, M. Przybylski, and M. Groettrup. 2004. Immunoproteasomes down-regulate presentation of a subdominant T cell epitope from lymphocytic choriomeningitis virus. J. Immunol. 173:3925-3934. (Pubitemid 39280756)
6. Betts, M. R., et al. 2005. Characterization of functional and phenotypic changes in anti-Gag vaccine-induced T cell responses and their role in protection after HIV-1 infection. Proc. Natl. Acad. Sci. U. S. A. 102:4512-4517.
7. Boes, B., et al. 1994. Interferon gamma stimulation modulates the proteolytic activity and cleavage site preference of 20S mouse proteasomes. J. Exp. Med. 179:901-909.
8. Boonnak, K., et al. 2008. Role of dendritic cells in antibody-dependent enhancement of dengue virus infection. J. Virol. 82:3939-3951.
9. Carrington, M., et al. 1999. HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage. Science 283:1748-1752.
10. Chapiro, J., et al. 2006. Destructive cleavage of antigenic peptides either by the immunoproteasome or by the standard proteasome results in differential antigen presentation. J. Immunol. 176:1053-1061.
11. Chun, T. W., et al. 1997. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 387:183-188.
12. Cresswell, P., A. L. Ackerman, A. Giodini, D. R. Peaper, and P. A. Wearsch. 2005. Mechanisms of MHC class I-restricted antigen processing and crosspresentation. Immunol. Rev. 207:145-157.
13. Dahlmann, B., T. Ruppert, L. Kuehn, S. Merforth, and P. M. Kloetzel. 2000. Different proteasome subtypes in a single tissue exhibit different enzymatic properties. J. Mol. Biol. 303:643-653.
14. Douek, D. C., et al. 2002. HIV preferentially infects HIV-specific CD4+ T cells. Nature 417:95-98.
15. Driscoll, J., M. G. Brown, D. Finley, and J. J. Monaco. 1993. MHC-linked LMP gene products specifically alter peptidase activities of the proteasome. Nature 365:262-264.
16. Fischer, W., et al. 2007. Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nat. Med. 13:100-106.
17. Gaczynska, M., K. L. Rock, T. Spies, and A. L. Goldberg. 1994. Peptidase activities of proteasomes are differentially regulated by the major histocompatibility complex-encoded genes for LMP2 and LMP7. Proc. Natl. Acad. Sci. U. S. A. 91:9213-9217.
18. Gallimore, A., H. Hengartner, and R. Zinkernagel. 1998. Hierarchies of antigen-specific cytotoxic T-cell responses. Immunol. Rev. 164:29-36.
19. Gao, X., et al. 2001. Effect of a single amino acid change in MHC class I molecules on the rate of progression to AIDS. N. Engl. J. Med. 344:1668-1675.
20. Gavioli, R., et al. 2008. The Tat protein broadens T cell responses directed to the HIV-1 antigens Gag and Env: implications for the design of new vaccination strategies against AIDS. Vaccine 26:727-737.
21. Gavioli, R., et al. 2004. HIV-1 tat protein modulates the generation of cytotoxic T cell epitopes by modifying proteasome composition and enzymatic activity. J. Immunol. 173:3838-3843.
22. Giodini, A., and M. L. Albert. 2010. A whodunit: an appointment with death. Curr. Opin. Immunol. 22:94-108.
23. Goulder, P. J., et al. 1997. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat. Med. 3:212-217.
24. Groettrup, M., et al. 1995. The interferon-gamma-inducible 11 S regulator (PA28) and the LMP2/LMP7 subunits govern the peptide production by the 20 S proteasome in vitro. J. Biol. Chem. 270:23808-23815.
25. Groll, M., et al. 1997. Structure of 20S proteasome from yeast at 2.4 Å resolution. Nature 386:463-471. (Pubitemid 27164066)
26. Groothuis, T. A., A. C. Griekspoor, J. J. Neijssen, C. A. Herberts, and J. J. Neefjes. 2005. MHC class I alleles and their exploration of the antigenprocessing machinery. Immunol. Rev. 207:60-76.
27. Hurley, C. K., et al. 2006. HLA typing and informatics, in immunobiology of the human MHC, p. 179-352. In J. A. Hansen (ed.), 13th International Histocompatibility Workshop protocols. IHWG Press, Seattle, WA.
28. Jansen, C. A., et al. 2005. High responsiveness of HLA-B57-restricted Gagspecific CD8+ T cells in vitro may contribute to the protective effect of HLA-B57 in HIV-infection. Eur. J. Immunol. 35:150-158.
29. Keele, B. F., et al. 2008. Characterization of the follicular dendritic cell reservoir of human immunodeficiency virus type 1. J. Virol. 82:5548-5561.
30. Kelleher, A. D., et al. 2001. Clustered mutations in HIV-1 gag are consistently required for escape from HLA-B27-restricted cytotoxic T lymphocyte responses. J. Exp. Med. 193:375-386.
31. Kiepiela, P., et al. 2007. CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat. Med. 13:46-53.
32. Kloetzel, P. M. 2001. Antigen processing by the proteasome. Nat. Rev. Mol. Cell Biol. 2:179-187.
33. Kloetzel, P. M., and F. Ossendorp. 2004. Proteasome and peptidase function in MHC-class-I-mediated antigen presentation. Curr. Opin. Immunol. 16: 76-81.
34. Kruger, E., U. Kuckelkorn, A. Sijts, and P. M. Kloetzel. 2003. The components of the proteasome system and their role in MHC class I antigen processing. Rev. Physiol. Biochem. Pharmacol. 148:81-104.
35. Kuckelkorn, U., et al. 2002. Link between organ-specific antigen processing by 20S proteasomes and CD8(+) T cell-mediated autoimmunity. J. Exp. Med. 195:983-990.
36. Lazaro, E., et al. 2009. Differential HIV epitope processing in monocytes and CD4 T cells affects cytotoxic T lymphocyte recognition. J. Infect. Dis. 200: 236-243.
37. Le Gall, S., P. Stamegna, and B. D. Walker. 2007. Portable flanking sequences modulate CTL epitope processing. J. Clin. Invest. 117:3563-3575.
38. Lopez, D., O. Calero, M. Jimenez, M. Garcia-Calvo, and M. Del Val. 2006. Antigen processing of a short viral antigen by proteasomes. J. Biol. Chem. 281:30315-30318.
39. Loureiro, J., and H. L. Ploegh. 2006. Antigen presentation and the ubiquitin-proteasome system in host-pathogen interactions. Adv. Immunol. 92:225-305.
40. Lowe, J., et al. 1995. Crystal structure of the 20S proteasome from the archaeon T. acidophilum at 3.4 Å resolution. Science 268:533-539.
41. Lucchiari-Hartz, M., et al. 2003. Differential proteasomal processing of hydrophobic and hydrophilic protein regions: contribution to cytotoxic T lymphocyte epitope clustering in HIV-1-Nef. Proc. Natl. Acad. Sci. U. S. A. 100:7755-7760.
42. Lucchiari-Hartz, M., et al. 2000. Cytotoxic T lymphocyte epitopes of HIV-1 Nef: generation of multiple definitive major histocompatibility complex class I ligands by proteasomes. J. Exp. Med. 191:239-252.
43. Macagno, A., et al. 1999. Dendritic cells up-regulate immunoproteasomes and the proteasome regulator PA28 during maturation. Eur. J. Immunol. 29:4037-4042.
44. Macagno, A., L. Kuehn, R. de Giuli, and M. Groettrup. 2001. Pronounced up-regulation of the PA28alpha/beta proteasome regulator but little increase in the steady-state content of immunoproteasome during dendritic cell maturation. Eur. J. Immunol. 31:3271-3280.
45. Milicic, A., et al. 2005. CD8+ T cell epitope-flanking mutations disrupt proteasomal processing of HIV-1 Nef. J. Immunol. 175:4618-4626.
46. Neijssen, J., et al. 2005. Cross-presentation by intercellular peptide transfer through gap junctions. Nature 434:83-88.
47. Nil, A., E. Firat, V. Sobek, K. Eichmann, and G. Niedermann. 2004. Expression of housekeeping and immunoproteasome subunit genes is differentially regulated in positively and negatively selecting thymic stroma subsets. Eur. J. Immunol. 34:2681-2689.
48. Ossendorp, F., et al. 2005. Differential expression regulation of the alpha and beta subunits of the PA28 proteasome activator in mature dendritic cells. J. Immunol. 174:7815-7822.
49. Pamer, E., and P. Cresswell. 1998. Mechanisms of MHC class I-restricted antigen processing. Annu. Rev. Immunol. 16:323-358.
50. Peachman, K. K., et al. 2005. Human dendritic cells and macrophages exhibit different intracellular processing pathways for soluble and liposome-encapsulated antigens. Immunobiology 210:321-333.
51. Rock, K. L., I. A. York, and A. L. Goldberg. 2004. Post-proteasomal antigen processing for major histocompatibility complex class I presentation. Nat. Immunol. 5:670-677.
52. Saric, T., et al. 2001. Major histocompatibility complex class I-presented antigenic peptides are degraded in cytosolic extracts primarily by thimet oligopeptidase. J. Biol. Chem. 276:36474-36481.
53. Saric, T., et al. 2002. An IFN-gamma-induced aminopeptidase in the ER, ERAP1, trims precursors to MHC class I-presented peptides. Nat. Immunol. 3:1169-1176.
54. Schmidtke, G., et al. 1999. How an inhibitor of the HIV-I protease modulates proteasome activity. J. Biol. Chem. 274:35734-35740.
55. Seifert, U., et al. 2004. Hepatitis C virus mutation affects proteasomal epitope processing. J. Clin. Invest. 114:250-259.
56. Seifert, U., et al. 2003. An essential role for tripeptidyl peptidase in the generation of an MHC class I epitope. Nat. Immunol. 4:375-379.
57. Shen, L., and K. L. Rock. 2006. Priming of T cells by exogenous antigen cross-presented on MHC class I molecules. Curr. Opin. Immunol. 18:85-91.
58. Sijts, A., et al. 2002. The role of the proteasome activator PA28 in MHC class I antigen processing. Mol. Immunol. 39:165-169.
59. Steers, N. J., C. R. Alving, and M. Rao. 2008. Modulation of immunoproteasome subunits by liposomal lipid A. Vaccine 26:2849-2859.
60. Steers, N. J., K. K. Peachman, S. R. McClain, C. R. Alving, and M. Rao. 2009. Human immunodeficiency virus type 1 Gag p24 alters the composition of immunoproteasomes and affects antigen presentation. J. Virol. 83:7049-7061.
61. Stove, V., and B. Verhasselt. 2006. Modelling thymic HIV-1 Nef effects. Curr. HIV Res. 4:57-64.
62. Tenzer, S., et al. 2004. Quantitative analysis of prion-protein degradation by constitutive and immuno-20S proteasomes indicates differences correlated with disease susceptibility. J. Immunol. 172:1083-1091.
63. Tenzer, S., et al. 2009. Antigen processing influences HIV-specific cytotoxic T lymphocyte immunodominance. Nat. Immunol. 10:636-646.
64. Toes, R. E., et al. 2001. Discrete cleavage motifs of constitutive and immunoproteasomes revealed by quantitative analysis of cleavage products. J. Exp. Med. 194:1-12.
65. Towne, C. F., et al. 2005. Leucine aminopeptidase is not essential for trimming peptides in the cytosol or generating epitopes for MHC class I antigen presentation. J. Immunol. 175:6605-6614.
66. Trombetta, E. S., and I. Mellman. 2005. Cell biology of antigen processing in vitro and in vivo. Annu. Rev. Immunol. 23:975-1028.
67. Turnbull, E. L., et al. 2006. HIV-1 epitope-specific CD8+ T cell responses strongly associated with delayed disease progression cross-recognize epitope variants efficiently. J. Immunol. 176:6130-6146.
68. Willberg, C. B., et al. 2010. Rapid progressing allele HLA-B35 Px restricted anti-HIV-1 CD8+ T cells recognize vestigial CTL epitopes. PLoS One 5:e10249.
69. Wu, L., and V. N. KewalRamani. 2006. Dendritic-cell interactions with HIV: infection and viral dissemination. Nat. Rev. Immunol. 6:859-868.
70. Yewdell, J. W. 2006. Confronting complexity: real-world immunodominance in antiviral CD8+ T cell responses. Immunity 25:533-543.
71. York, I. A., N. Bhutani, S. Zendzian, A. L. Goldberg, and K. L. Rock. 2006. Tripeptidyl peptidase II is the major peptidase needed to trim long antigenic precursors, but is not required for most MHC class I antigen presentation. J. Immunol. 177:1434-1443.